Dependence on Sales to Roche Group and QIAGEN Group
First written in FY2016. 8 of 13 entries say "Worsened", first in FY2017. Latest entry: FY2026.
Precision System Science moved to the "Worse" side of this theme in 2017, 6 years before the typical company in this theme (2023).
The whole theme swung hardest in 2017: 12 of 76 companies on the "Worse" side.
29 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「Sales to ELITechGroup S.p.A. of Italy (hereinafter, “ELITechGroup”) accounted for 62.4% of the Group's sales for the fiscal year ended June 2026, a high level.」
The ratio of sales to ELITechGroup rose from 55.0% in FY2025 to 62.4%, increasing concentration in a specific customer. - FY2025WorsenedAnnual report
「ODM customers such as ELITechGroup accounted for approximately 76% of the Group's sales for the fiscal year ended June 2025, indicating a high level of dependence.」
Dependence on ODM customers rose from slightly more than 70% disclosed for the previous fiscal year to approximately 76%. It was also disclosed that ELITechGroup alone accounted for 55.0% of sales. - FY2025-H1Dependence on ELITechGroup explicitly disclosedAnnual report
「The Group has historically maintained a strong cooperative relationship with ELITechGroup, which accounts for slightly more than 50% of the Group's sales, and entered into a 5-year OEM product supply agreement with ELITechGroup,」
The disclosure specified that ELITechGroup accounted for slightly more than 50% of the Group's sales in relation to dependence on specific customers. - FY2024WorsenedAnnual report
「OEM customers such as ELITechGroup accounted for slightly more than 70% of the Group's sales for the fiscal year ended June 2024, indicating a high level of dependence.」
In addition to the previously disclosed dependence on 4 specific overseas customers, the Group disclosed that dependence on all OEM customers was slightly more than 70%. - FY2024-Q2MaterialisedAnnual report
「The Company reasonably estimated the expenses and losses arising from the business-operations reform being pursued by the Group and the filing by business partner NanoString Technologies, Inc. (U.S.) for protection under Chapter 11 of the U.S. Bankruptcy Code, among other matters, and recorded the total amount of ¥242 million as an extraordinary loss for business-structure improvement costs. As a result, the quarterly net loss attributable to owners of the parent was ¥727 million, compared with a quarterly net loss attributable to owners of the parent of ¥466 million in the same period of the previous year.」
In relation to dependence on major customers and business partners, NanoString Technologies, Inc.'s filing under Chapter 11 of the U.S. Bankruptcy Code actually occurred, and an extraordinary loss of ¥242 million, including the associated expenses and losses, was recorded. - FY2023MitigatedAnnual report
「Sales to the ELITechGroup, QIAGEN Group, Thermo Fisher Group and NanoString accounted for 48.6% of the Group's sales for the fiscal year ended June 2023.」
Sales to 4 specific overseas OEM customers declined from 53.6% in the previous fiscal year to 48.6%, but still accounted for approximately half of sales. - FY2022WorsenedAnnual report
「Sales to the ELITechGroup, QIAGEN Group, Thermo Fisher Group and NanoString accounted for 53.6% of the Group's sales for the fiscal year ended June 2022.」
The concentration of sales shifted from the previous 3 groups to 4 companies and groups, while the sales ratio rose from 50.7% in the previous fiscal year to 53.6%. - FY2021WorsenedAnnual report
「Sales to the ELITechGroup, QIAGEN Group and Roche Group accounted for 50.7% of the Group's sales for the fiscal year ended June 2021.」
The sales ratio for the 3 groups rose from 50.1% in the previous fiscal year to 50.7%, increasing concentration in specific customers. - FY2020MitigatedAnnual report
「Sales to the ELITechGroup, QIAGEN Group and Roche Group accounted for 50.1% of the Group's sales for the fiscal year ended June 2020.」
The sales ratio for the 3 groups declined slightly from 50.5% in the previous fiscal year to 50.1%, but still accounted for approximately half of sales. - FY2019WorsenedAnnual report
「Sales to the ELITechGroup, QIAGEN Group and Roche Group accounted for 50.5% of the Group's sales for the fiscal year ended June 2019.」
The sales ratio for the 3 groups rose from 40.2% in the previous fiscal year to 50.5%, increasing concentration in specific customers. - FY2018WorsenedAnnual report
「Sales to the ELITechGroup, QIAGEN Group and Roche Group accounted for 40.2% of the Group's sales for the fiscal year ended June 2018.」
The concentration of sales shifted from the Roche Group and QIAGEN Group to 3 groups, while the sales ratio rose from 38.6% in the previous fiscal year to 40.2%. - FY2017WorsenedAnnual report
「Sales to the Roche Group and QIAGEN Group accounted for 38.6% of the Group's sales for the fiscal year ended June 2017.」
The ratio of sales to the Roche Group and QIAGEN Group rose from 37.9% in the previous fiscal year to 38.6%, increasing concentration in specific customers. - FY2016First statedAnnual report
「Sales to the Roche Group and QIAGEN Group accounted for 37.9% of the Group's sales for the fiscal year ended June 2016.」
The Group disclosed that sales to the 2 groups accounted for 37.9% of total sales and cited the impact of the customers' management and business strategies.